Primary objective:
To compare the pharmacodynamics of insulin glulisine and insulin lispro injected
subcutaneously before three 500 kcal standard meals during a 12 hour day, in obese subjects
with type 2 diabetes.
Secondary objectives:
- To compare the pharmacokinetics of insulin glulisine and insulin lispro in obese
subjects with type 2 diabetes, injected subcutaneously before three standard meals
during a 12-hour day.
- The safety of insulin glulisine, the relationship of the pharmacodynamics and
pharmacokinetics with skin thickness and C-peptide, non-esterified fatty acid,
triglyceride and β-hydroxybutyrate levels in these subjects will also be assessed.